Related Experiment Video
Updated: Jun 5, 2026

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
Published on: January 10, 2015
[Pharmacotherapy for Tobacco Dependence: Implementation of the Current G-BA Resolution - Information from Section E3
Klaas Frederik Franzen1, Matthias Raspe2, Matthias Urlbauer3
1Universität zu Lübeck Sektion Medizin, Medizinische Klinik III, Deutschland, Lübeck.
Abstract:
The recent resolution of the Federal Joint Committee (G-BA) amending section §14a of the Pharmaceutical Directive and introducing Annex IIa represents a major advancement in the clinical management of tobacco dependence in Germany. This editorial outlines the regulatory prerequisites for prescribing pharmacological smoking-cessation therapies, including the diagnostic confirmation of severe tobacco dependence (ICD-10 F17.2), assessment via the Fagerström Test for Cigarette Dependence, and mandatory participation in an evidence-based cessation program. Approved therapeutic options, such as mono- or combination nicotine replacement therapy and varenicline, are described alongside considerations for implementation in both outpatient and inpatient care settings. The text further discusses current limitations of the resolution, including the three-year restriction on repeat prescriptions and the insufficient integration of users of heated tobacco products and e-cigarettes. Overall, the resolution is assessed as an important milestone toward structured treatment of a chronic relapsing disorder, while highlighting areas for future improvement.
Related Concept Videos
Drug Dependence
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
CNS Depressants: Alcohol and Nicotine
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
